Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zinzani, P.
Right arrow Articles by Tura, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zinzani, P.
Right arrow Articles by Tura, S
Haematologica, Vol 85, Issue 11, 1135-1139
Copyright © 2000 by Ferrata Storti Foundation

Journal Article

Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia

PL Zinzani, M Bendandi, M Magagnoli, P Albertini, D Rondelli, V Stefoni, M Tani, and S Tura

Istituto di Ematologia e Oncologia Medica "Seragnoli", Policlinico S. Orsola, Via Massarenti 9, 40121 Bologna, Italy. plzinzo@med.unibo.it

BACKGROUND AND OBJECTIVES: A study update to assess long-term survival following fludarabine salvage treatment in previously treated patients with chronic lymphocytic lymphoma (CLL). DESIGN AND METHODS: From September 1992 to December 1995, 74 patients with advanced, relapsing B-cell CLL were enrolled in the study. Fludarabine was given for 5 consecutive days at the dose of 25 mg/m2/day in a 30 min infusion. Treatment was repeated every 28 days for a maximum of 6 courses.E RESULTS. Nineteen (26%) patients achieved a complete response (CR) and 20 (27%) patients had a partial response (PR), giving an overall response rate of 53%. The median overall survival was 68 months, and there was a strong negative correlation with the number of previous treatments. The median time to progression was 18 months for patients who achieved a CR and 12 months for those with a PR. INTERPRETATION AND CONCLUSIONS: The results obtained with fludarabine alone in this subset of CLL patients indicate the existence of a conspicuous disease-free survival period. This time window could be used to consolidate the initial response with either biological approaches or high-dose therapeutic strategies such as autologous bone marrow transplantation, with the aim of eventual eradication of the disease.


This article has been cited by other articles:


Home page
 JCOHome page
V. A. Morrison, K. R. Rai, B. L. Peterson, J. E. Kolitz, L. Elias, F. R. Appelbaum, J. D. Hines, L. Shepherd, R. A. Larson, and C. A. Schiffer
Therapy-Related Myeloid Leukemias Are Observed in Patients With Chronic Lymphocytic Leukemia After Treatment With Fludarabine and Chlorambucil: Results of an Intergroup Study, Cancer and Leukemia Group B 9011
J. Clin. Oncol., September 15, 2002; 20(18): 3878 - 3884.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Yamauchi, B. J. Nowak, M. J. Keating, and W. Plunkett
DNA Repair Initiated in Chronic Lymphocytic Leukemia Lymphocytes by 4-Hydroperoxycyclophosphamide Is Inhibited by Fludarabine and Clofarabine
Clin. Cancer Res., November 1, 2001; 7(11): 3580 - 3589.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. S. Copur, P. Ledakis, J. Muhvic, M. Erman, I. Celik, G. Tekuzman, M. Marchetti, G. Barosi, L. N. Liberato, S. J. Proctor, et al.
Fludarabine for Chronic Lymphocytic Leukemia
N. Engl. J. Med., April 12, 2001; 344(15): 1166 - 1168.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2000 by the Ferrata Storti Foundation.